ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.36 and traded as high as $7.16. ImmuCell shares last traded at $6.88, with a volume of 14,227 shares traded.
ImmuCell Price Performance
The company has a market capitalization of $61.02 million, a price-to-earnings ratio of -96.41 and a beta of 0.30. The company has a quick ratio of 2.21, a current ratio of 4.12 and a debt-to-equity ratio of 0.30. The company has a 50 day simple moving average of $5.98 and a 200 day simple moving average of $5.40.
ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%. The business had revenue of $8.07 million during the quarter.
Institutional Investors Weigh In On ImmuCell
A number of large investors have recently modified their holdings of ICCC. Dauntless Investment Group LLC acquired a new stake in shares of ImmuCell in the fourth quarter valued at about $676,000. Citadel Advisors LLC acquired a new stake in shares of ImmuCell in the fourth quarter valued at about $149,000. Northern Trust Corp grew its stake in shares of ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after buying an additional 14,982 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its stake in shares of ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after buying an additional 12,178 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after buying an additional 7,878 shares in the last quarter. Institutional investors and hedge funds own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
